Navigation Links
C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc
Date:6/2/2011

MORRISTOWN, N.J., June 2, 2011 /PRNewswire/ -- C3i, a world leader in clinical trial support services, today announced the signing of its newest client, XBiotech, Inc. XBiotech, located in Austin, TX, is a leader in the development of therapeutic antibodies, and has launched the first "True Human" monoclonal antibody into clinical trials. XBiotech's lead drug candidate uniquely blocks pathologic inflammatory responses and is being developed to treat diseases such as cancer, atherosclerosis, and diabetes. C3i, a Gold level member in Oracle PartnerNetwork (OPN), will provide a full-service technical solution to support its program of promising clinical trials.

Leveraging its proprietary help desk support and end user training systems, in conjunction with Oracle's market-leading Oracle Clinical and Oracle Remote Data Capture clinical data management system, C3i provides a turnkey solution to meet the needs of scientifically focused organizations like XBiotech.

C3i will provide XBiotech with global site training and support services to enable participating clinical sites to rapidly become proficient in the use of Oracle Remote Data Capture, a leading data capture solution that allows clinical site personnel to collect study patients' data at the investigator site and facilitates higher quality data.

XBiotech required a world-class data management system on which to build and manage its clinical trials and the support of consultants with the technical expertise and industry experience necessary to get their trials up and running quickly.

"C3i's comprehensive services combined with Oracle Health Sciences solutions provide us with the opportunity to manage our clinical data in a top-tier system, that is hosted and operated with expertise and experience," said Michael Stecher M.D., XBiotech's Medical Director.

"We are excited to welcome a growing company like XBiotech as a client. We believe they exemplify the still emerging potential of the important biotech industry." added Joel Morse, C3i's CEO. "Our business process outsourcing solution is well-suited to XBiotech's current data management and IT requirements, and provides them with a flexible model to accommodate their growth."

Tyler Prince, group vice president, North America Sales, Applications and Public Sector Alliances & Channels, Oracle pointed out that "C3i's full range of tailored services illustrate the value that Oracle partners bring to our joint customers."

About C3i: Headquartered in Morristown, New Jersey, C3i Inc. has global operations in North America, Europe, India and China. Their 1200 employees provide systems implementation, technology training, multi-lingual help desk, hardware provisioning, and break/fix, asset management, and user/application administration services for pharmaceutical sales and clinical professionals worldwide. To learn more, visit www.c3i-inc.com.

C3i is a Gold-level member of Oracle® PartnerNetwork.

About XBiotech: XBiotech, located in Austin, TX, is a leader in the development of therapeutic antibodies, and has launched the first "True Human" monoclonal antibody into clinical trials. XBiotech's lead drug candidate uniquely blocks pathologic inflammatory responses and is being developed to treat diseases such as cancer, atherosclerosis, and diabetes. To learn more, visit www.xbiotech.com

Trademarks

Oracle and Java are registered trademarks of Oracle and/or its affiliates.

Contact:

Dave Hanaman
C3i Inc
973-401-4677
dhanaman@c3i-inc.com


'/>"/>
SOURCE C3i
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Physicians Growing Demand for Point-of-Care Resources Spawns iPointOfCare From Top Continuing Medical Education Provider; DIME
2. St. Lukes Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure
3. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
4. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
5. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
6. Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
7. Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World
8. Understanding how glasses relax provides some relief for manufacturers
9. ERT Awarded over $10 Million of ePRO Business from Major Pharma - Increasing its Position as a Leading ePRO Provider
10. Magellan Biosciences Announces Agreement with Bruker to Provide Microbiology Tools to Battle Drug Resistance
11. New model of whiskers provides insight into sense of touch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... CHICAGO , December 5, 2016 ... report, "Cell Expansion Market, by Products (Consumable, Instruments, ... Applications (Regenerative Medicine and Stem Cell Research, Cancer, ... Research Institutes, Cell Banks) - Global Revenue, Trends, ... by Scalar Market Research, the global cell expansion ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... report "DNA Sequencing - Technologies, Markets and Companies" ... ... report briefly reviews basics of human genome variations, development of ... are described as well as companies developing them. Various applications ...
(Date:12/4/2016)... and CAMBRIDGE, Mass. and ... Dec. 4, 2016 SystemOne, a company ... software platforms for the developing world, and Daktari ... a reality with its portable and ultrasensitive immunoassay-based ... a development and license agreement to integrate Daktari,s ...
(Date:12/2/2016)... -- CytRx Corporation (NASDAQ: CYTR ), a ... announced the appointment of Earl Warren Brien , ... healthcare investor, to its Board of Directors. ... strategic experience at the highest level," said Steven ... of the world,s leading orthopedic surgeons, Dr. Brien has ...
Breaking Biology Technology:
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil ... corrections and monitoring, announced today that it has offered ... an independent technology judge determine who has the largest ... telephone calling platform, and the best customer service. ... of what we do – which clearly is not ...
(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...
Breaking Biology News(10 mins):